Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Therapy-related MDS

Uma Borate • 1 Jun 2020
EHA 2020
Myelodysplastic Syndromes

Uma Borate, MD, of the Oregon Health & Science University, Portland, OR, discusses therapy-related myelodysplastic syndromes (MDS) and their under-representation in historic MDS trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Uma Borate

Advances made in MDS classification and risk stratification: ongoing work & future perspectives 8:48
Advances made in MDS classification and risk stratification: ongoing work & future perspectives
Luca Lanino et al. • 28 Jun 2025
New trends in CHIP/CCUS: impact of CH on transplant outcomes & distinguishing between MDS & CCUS
Coleman Lindsley et al. • 16 Jul 2024
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
Ruxolitinib plus venetoclax in heavily pretreated patients with R/R AML 1:21
Ruxolitinib plus venetoclax in heavily pretreated patients with R/R AML
Uma Borate • 8 Dec 2023

Related Videos

Updated results from a Phase II trial of elritercept in LR-MDS 2:27
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee • 8 Dec 2025
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination 3:53
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination
Moshe Mittelman • 7 Dec 2025
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS 1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial 1:11
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
Amer Zeidan • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals